10/645,934

(Please scan into case)

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau129pxo

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS	5	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS	6	MAY 11	KOREAPAT updates resume
NEWS	7	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	8	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS	9	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS	10	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	11	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	12	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	13	JUl 11	CHEMSAFE reloaded and enhanced
NEWS	14	JUl 14	FSTA enhanced with Japanese patents
NEWS	15	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	16	AUG 09	INSPEC enhanced with 1898-1968 archive

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 21:13:08 ON 16 AUG 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'REGISTRY' ENTERED AT 21:15:02 ON 16 AUG 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 AUG 2006 HIGHEST RN 901654-60-2
DICTIONARY FILE UPDATES: 15 AUG 2006 HIGHEST RN 901654-60-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10645934.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Me,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,H
G2 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1
L2 1411 LL

=> search l1 full
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.

FULL SEARCH INITIATED 21:15:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 530967 TO ITERATE

100.0% PROCESSED 530967 ITERATIONS 271 ANSWERS
SEARCH TIME: 00.00.05

L3 271 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.14	172.77

FILE 'CAPLUS' ENTERED AT 21:16:15 ON 16 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 Aug 2006 VOL 145 ISS 8
FILE LAST UPDATED: 15 Aug 2006 (20060815/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 25 L3

=> d l4 fbib ab hitstr 1-25

L4 ANSWER 1 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:343083 CAPLUS
DN 144:381949
TI Method for screening transmembrane enzyme inhibitor, specifically β-secretase selective inhibitor as drug for memory disorders
IN Tarui, Naoki
PA Takeda Pharmaceutical Company Limited, Japan
SO PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006038684	A1	20060413	WO 2005-JP18587	20050930

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,

NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

JP 2004-290784 A 20041001

AB A method is provided for screening a compound capable of binding to a transmembrane region of a transmembrane enzyme (e.g., aspartate proteinase), and thereby, inhibiting its enzymic activity. The method is characterized in that it comprises using: (a) a protein having a part or the whole of the amino acid sequence of the enzyme wherein a region including the activity center of the transmembrane enzyme and a part or the whole of the transmembrane region are contained; and optionally together with (b) a protein having a part of the amino acid sequence of the transmembrane enzyme wherein a region including the activity center is contained while a part or the whole of the transmembrane region is lacking, and measuring the binding of a test substance to each protein and the enzymic activity of each protein. Further, provided is a screening kit comprising the above proteins (a) and (b). Also provided is a β-secretase selective inhibitor comprising a substance capable of inhibiting the enzyme by binding to the transmembrane region of β-secretase, specifically a preventive/therapeutic agent for Alzheimer disease, Down syndrome or senile memory disorders.

IT 212571-56-7 712263-50-8 746589-34-4
792890-60-9 882516-77-0
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(method for screening transmembrane enzyme inhibitor, specifically β-secretase selective inhibitor as drug for memory disorders)

RN 212571-56-7 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 712263-50-8 CAPLUS
CN 2-Naphthaleneethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[(4'-methyl[1,1'-biphenyl]-4-yl)methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746589-34-4 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 792890-60-9 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-N,N-diethyl-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 882516-77-0 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, N-oxide, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:472138 CAPLUS
DN 143:26619
TI Preparation of heterocyclic compounds as hypolipidemic agents
IN Lohray, Braj Bhushan; Lohray, Vidya Bhushan
PA Cadila Healthcare Limited, India
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005049589	A2	20050602	WO 2004-IN319	20041014
WO 2005049589	A3	20050915		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IN 2003-MU1064 A 20031014

OS MARPAT 143:26619
AB Title compds. I [G = NR1(CH2)pY; A = (hetero)aryl, etc.; B = O, S; Ar = optionally substituted divalent (hetero)aromatic, etc.; R1 = H, alk(en/yn)yl, etc.; n, m, p = 1-3; Y = acyl, carboxy, etc.] are prepared For instance, Et [4-[2-(2,3-dihydrobenzo[1,4]oxazin-4-yl)ethoxy]benzylamino]acetate is prepared by treatment of 4-[2-(2,3-dihydrobenzo[1,4]oxazin-4-yl)ethoxy]benzaldehyde with glycine Et ester•HCl (MeOH, Et3N, NaBH4, 30°, 1 h). I showed good serum glucose, lipid and cholesterol lowering activity; a selected example compound at 3 mg/kg/day showed a 57% reduction in serum glucose.
IT 852816-64-9P, Ethyl [((6-benzyloxynaphthalen-2-yl)methyl)amino]acetate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as hypolipidemic agents)
RN 852816-64-9 CAPLUS
CN Glycine, N-[[6-(phenylmethoxy)-2-naphthalenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:532544 CAPLUS
DN 139:95481

TI Remedies for mild recognition deficit
IN Miyamoto, Masaomi; Takahashi, Hideki; Fukumoto, Hiroaki; Ohkawa, Shigenori
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2003055521	A1	20030710	WO 2002-JP13478		20021225
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				JP 2001-394236	A	20011226
	CA 2471531	AA	20030710	CA 2002-2471531		20021225
				JP 2001-394236	A	20011226
				WO 2002-JP13478	W	20021225
	AU 2002367106	A1	20030715	AU 2002-367106		20021225
				JP 2001-394236	A	20011226
				WO 2002-JP13478	W	20021225
	JP 2003252795	A2	20030910	JP 2002-374586		20021225
				JP 2001-394236	A	20011226
	EP 1459764	A1	20040922	EP 2002-790853		20021225
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
				JP 2001-394236	A	20011226
				WO 2002-JP13478	W	20021225
	US 2005085553	A1	20050421	US 2003-499354		20021225
				JP 2001-394236	A	20011226
				WO 2002-JP13478	W	20021225

OS MARPAT 139:95481
AB It is intended to provide remedies for mild recognition deficit which comprise compds. having an effect of inhibiting the production, secretion, aggregation and/or accumulation of β-amyloid proteins, prodrugs thereof or salts of the same and inhibit the progress of mild recognition deficit into Alzheimer's disease using the same.
IT 212573-57-4P 212573-58-5P 365276-12-6P
427885-33-4P 557086-14-3P 557086-15-4P
557086-16-5P 557086-17-6P 557086-18-7P
557086-19-8P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(remedies for mild recognition deficit)
RN 212573-57-4 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 212573-58-5 CAPLUS
CN 2-Naphthalenemethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 365276-12-6 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride, monohydrate, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

● H2O

RN 427885-33-4 CAPLUS
CN 2-Naphthalenemethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 557086-14-3 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-6-[(4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 557086-15-4 CAPLUS
CN 2-Naphthaleneethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[(4'-methyl[1,1'-biphenyl]-4-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 557086-16-5 CAPLUS
CN 2-Naphthaleneethanamine, 1,2,3,4-tetrahydro-6-[(4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 557086-17-6 CAPLUS
CN 2-Naphthaleneethanamine, 6-[(2',4'-dimethoxy[1,1'-biphenyl]-4-yl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 557086-18-7 CAPLUS
CN 2-Naphthaleneethanamine, 6-[[4-(1,3-benzodioxol-5-yl)phenyl]methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 557086-19-8 CAPLUS
CN 2-Naphthaleneethanamine, 6-[(3',4'-dimethoxy[1,1'-biphenyl]-4-yl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:469791 CAPLUS
DN 137:325223
TI Synthesis and pharmacological analysis of high affinity melatonin receptor ligands
AU Chu, Guo-Hua; Witt-Enderby, Paula A.; Jones, Marla; Li, Pui-Kai
CS Department of Medicinal Chemistry and Pharmaceutics, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA, 15282, USA
SO Chemical & Pharmaceutical Bulletin (2002), 50(2), 272-275
CODEN: CPBTAL; ISSN: 0009-2363
PB Pharmaceutical Society of Japan
DT Journal
LA English
OS CASREACT 137:325223
AB We report the synthesis and radioligand binding anal. of a series of naphthalenic melatonin receptor ligands, N-[2-(7-alkoxy-2-methoxy-1-naphthyl)ethyl]propionamide, e.g. I. This series of ligands exhibits subpicomolar binding affinity to both melatonin receptors MT1 and MT2 melatonin receptors expressed in chinese hamster ovary (CHO) cells.
IT 473835-59-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of N-[2-(7-alkoxy-2-methoxy-1-naphthyl)ethyl]propionamide and pharmacol. anal. of high affinity melatonin receptor ligands)
RN 473835-59-5 CAPLUS
CN Propanamide, N-[2-[2-methoxy-7-(phenylmethoxy)-1-naphthalenyl]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:391566 CAPLUS
DN 136:391023
TI Pharmaceutical compositions containing copolyvidone
IN Ishida, Hajime; Fukuta, Makoto
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002040054	A1	20020523	WO 2001-JP10016	20011116
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				JP 2000-351223	A 20001117
	CA 2428817	AA	20020523	CA 2001-2428817	20011116
				JP 2000-351223	A 20001117
				WO 2001-JP10016	W 20011116
	AU 2002014305	A5	20020527	AU 2002-14305	20011116
				JP 2000-351223	A 20001117
				WO 2001-JP10016	W 20011116
	JP 2002212063	A2	20020731	JP 2001-351013	20011116
	JP 3633895	B2	20050330		
				JP 2000-351223	A 20001117
	EP 1334732	A1	20030813	EP 2001-982812	20011116
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				JP 2000-351223	A 20001117
				WO 2001-JP10016	W 20011116
	US 2004018239	A1	20040129	US 2003-416172	20030508
				JP 2000-351223	A 20001117
				WO 2001-JP10016	W 20011116
	JP 2004300160	A2	20041028	JP 2004-218996	20040727
				JP 2000-351223	A 20001117
				JP 2001-351013	A3 20011116

OS MARPAT 136:391023
AB Disclosed is a stabilized pharmaceutical composition which comprises a drug unstable in polyethylene glycol-containing prepns., and a coating agent which comprises a copolyvidone and with which the drug is coated instead of

polyethylene glycol. An original tablet containing (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide 4, lactose 101.6, corn starch 20, hydroxypropyl cellulose 4, and magnesium stearate 0.4 mg was coated with a coating material containing hydroxypropyl Me cellulose 3.74, copolyvidone 0.75, titanium oxide 0.5, and yellow iron oxide 0.01 mg to obtain a film-coated tablet. The obtained tablet showed improved storage stability as compare with a tablet without containing copolyvidone.

IT 365276-12-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns having improved storage stability containing copolyvidone)

RN 365276-12-6 CAPLUS

CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride, monohydrate, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

● H2O

IT 212571-56-7 212573-57-4 212573-58-5
212573-59-6 212573-60-9 212573-61-0
212573-62-1 212573-63-2 212573-64-3
212573-65-4 427885-33-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns having improved storage stability containing copolyvidone)

RN 212571-56-7 CAPLUS

CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 212573-57-4 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 212573-58-5 CAPLUS
CN 2-Naphthalenemethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 212573-59-6 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-6-[(4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 212573-60-9 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-N,N-diethyl-1,2,3,4-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 212573-61-0 CAPLUS
CN 2-Naphthaleneethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[(4'-methyl[1,1'-biphenyl]-4-yl)methoxy]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 212573-62-1 CAPLUS
CN 2-Naphthaleneethanamine, 1,2,3,4-tetrahydro-6-[(4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]-N,N-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 212573-63-2 CAPLUS
CN 2-Naphthaleneethanamine, 6-[(2',4'-dimethoxy[1,1'-biphenyl]-4-yl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 212573-64-3 CAPLUS
CN 2-Naphthaleneethanamine, 6-[[4-(1,3-benzodioxol-5-yl)phenyl]methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 212573-65-4 CAPLUS
CN 2-Naphthaleneethanamine, 6-[(3',4'-dimethoxy[1,1'-biphenyl]-4-yl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 427885-33-4 CAPLUS
CN 2-Naphthalenemethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dipropyl- (9CI) (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:117102 CAPLUS
DN 137:257216
TI Conformationally restrained analogues of sympathomimetic catecholamines, Synthesis and adrenergic activity of 5,6- and 6,7-dihydroxy-3,4-dihydrospiro[naphthalen-1(2H)-2',5'-morpholines]
AU Balsamo, Aldo; Lapucci, Annalina; Manera, Clementina; Martinelli, Adriano; Nencetti, Susanna; Orlandini, Elisabetta; Calderone, Vincenzo; Giannaccini, Gino; Nieri, Paola
CS Facolta di Farmacia, Dipartimento di Scienze Farmaceutiche, Universita di

Pisa, Pisa, 56100, Italy
SO European Journal of Medicinal Chemistry (2002), 37(1), 11-22
CODEN: EJMCA5; ISSN: 0223-5234
PB Editions Scientifiques et Medicales Elsevier
DT Journal
LA English
OS CASREACT 137:257216
AB The 5,6-dihydroxy-3,4-dihydrospiro[naphthalen-1(2H)-2',5'-morpholine] and 6,7-dihydroxy-3,4-dihydrospiro[naphthalen-1(2H)-2',5'-morpholine] and their N-iso-Pr derivs. (DDSNMs), which can be viewed as the result of the combination of the structure of the 2-(3,4-dihydroxyphenyl)morpholines (DPMs) with the structure of the corresponding 1-(aminomethyl)-5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthalen-ol or 1-(aminomethyl)-6,7-dihydroxy-1,2,3,4-tetrahydro-1-naphthalen-ol (1-AMDTNs) were synthesized. The new compds. DDSNMs were assayed for their α- and β-adrenergic properties by means of binding expts. and functional tests and the results were compared with those obtained for catecholamines and the previously described morpholine and tetrahydronaphthalene derivs. The affinity and activity indexes thus obtained indicate in general a low ability of the new compds. to interact with the α- and β-adrenoceptors, which, in all cases, was lower than that of the corresponding morpholine and tetrahydronaphthalene analogs.
IT 462100-12-5 462100-13-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(conformationally restrained analogs of sympathomimetic catecholamines Synthesis and adrenergic activity of 5,6- and 6,7-dihydroxy-3,4-dihydrospiro[naphthalen-1(2H)-2',5'-morpholines])
RN 462100-12-5 CAPLUS
CN 1-Naphthalenol, 1-(aminomethyl)-1,2,3,4-tetrahydro-5,6-bis(phenylmethoxy)-(9CI) (CA INDEX NAME)



RN 462100-13-6 CAPLUS
CN 1-Naphthalenol, 1-(aminomethyl)-1,2,3,4-tetrahydro-6,7-bis(phenylmethoxy)-(9CI) (CA INDEX NAME)



IT 462100-14-7P 462100-15-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(conformationally restrained analogs of sympathomimetic catecholamines Synthesis and adrenergic activity of 5,6- and 6,7-dihydroxy-3,4-dihydrospiro[naphthalen-1(2H)-2',5'-morpholines])

RN 462100-14-7 CAPLUS
CN Acetamide, 2-chloro-N-[[1,2,3,4-tetrahydro-1-hydroxy-5,6-bis(phenylmethoxy)-1-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 462100-15-8 CAPLUS
CN Acetamide, 2-chloro-N-[[1,2,3,4-tetrahydro-1-hydroxy-6,7-bis(phenylmethoxy)-1-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:850932 CAPLUS
DN 135:371744
TI Preparation of 2-[2-amino- or 2-(N-heterocyclyl)ethyl]-6-(4-biphenylylmethoxy)tetralin derivatives as β-secretase inhibitors
IN Miyamoto, Masaomi; Matsui, Junji; Fukumoto, Hiroaki; Tarui, Naoki
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001087293	A1	20011122	WO 2001-JP4144	20010518
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			JP 2000-152758	A 20000519
CA 2407088	AA	20011122	CA 2001-2407088	20010518

				JP 2000-152758	A	20000519
				WO 2001-JP4144	W	20010518
AU 2001058771		A5	20011126	AU 2001-58771		20010518
				JP 2000-152758	A	20000519
				WO 2001-JP4144	W	20010518
JP 2002037731		A2	20020206	JP 2001-148811		20010518
				JP 2000-152758	A	20000519
EP 1283039		A1	20030212	EP 2001-932128		20010518
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
				JP 2000-152758	A	20000519
				WO 2001-JP4144	W	20010518
US 2004110743		A1	20040610	US 2002-275339		20021107
				JP 2000-152758	A	20000519
				WO 2001-JP4144	W	20010518
US 2005228020		A1	20051013	US 2005-142885		20050601
				JP 2000-152758	A	20000519
				WO 2001-JP4144	W	20010518
				US 2002-275339	A3	20021107

OS MARPAT 135:371744

AB β-Secretase inhibitors are provided, which contain compds. of the general formula (I) or salts thereof [wherein Ar is an aromatic group; X is a divalent group selected from among O, S, CO, SO, SO2, NR8, CONR8, SO2NR8 and CO2 (wherein R8 is hydrogen or optionally substituted hydrocarbyl or acyl), a divalent C1-6 aliphatic hydrocarbon group which may contain one or two of these divalent groups, or a free valency; Y is a divalent group selected from among O, S, CO, SO, SO2, NR8, CONR8, SO2NR8, and CO2, or a divalent C1-6 aliphatic hydrocarbon group which may contain one or two of these divalent groups; R1 and R2 are each hydrogen or optionally substituted hydrocarbon group or NR1R2 together forms an optionally substituted heterocyclyl; and A is a ring which may be further substituted]. These compds. are useful for the prevention or treatment of (1) neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, (2) neuropathy during cerebral vascular disorders, head trauma, spinal code injury, after effect of encephalitis, or cerebral palsy, (3) memory disorders, and (4) mental disorders owing to increasing the secretion of amyloid precursor protein N-terminal fragment (aAPPα) and/or inhibiting the production and secretion of β-amyloid protein. Thus, etherification of 4-chloromethylbiphenyl (preparation given) with (R)-(+)-N,N-dimethyl-6-hydroxytetralin-2-acetamide (preparation given) in the presence of K2CO3 in DMF at 80° for 3 h gave 96.7% (R)-N,N-dimethyl-6-(4-biphenylylmethoxy)tetralin-2-acetamide which was reduced by sodium dihydro-bis(2-methoxyethoxy)aluminate in PhMe at room temperature for 1.5 h to give, after workup using 4 N aqueous NaOH and acidification with concentrated HCl, (R)-(+)-6-(4-biphenylylmethoxy)-2-[2-(dimethylamino)ethyl]tetralin hydrochloride monohydrate (II). II and 6-(4-biphenylylmethoxy)-2-[2-(piperidin-1-yl)ethyl]tetralin hydrochloride showed IC50 of 2.93 + 10-6 and 3.49 + 10-7 M, resp., against recombinant β-secretase. Formulations, e.g. a tablet formulation containing II, lactose, corn starch, corn starch paste, magnesium stearate, and CM-cellulose calcium salt, were also described.

IT 212571-45-4P, 6-(4-Biphenylylmethoxy)-2-[2-(diethylamino)ethyl]tetralin hydrochloride 212571-54-5P, (R)-(+)-6-(4-Biphenylylmethoxy)-2-[2-(dimethylamino)ethyl]tetralin hydrochloride 212571-74-9P, 6-(4-Biphenylylmethoxy)-2-(2-aminoethyl)tetralin hydrochloride 212571-83-0P, 6-(4-Biphenylylmethoxy)-2-[2-(methylamino)ethyl]tetralin hydrochloride 373383-57-4P 373386-73-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (amino- or N-heterocyclylethyl)(biphenylylmethoxy)tetralin derivs. as β-secretase inhibitors having neurotrophic factor-like activity)

RN 212571-45-4 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-N,N-diethyl-1,2,3,4-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-54-5 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 212571-74-9 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-83-0 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 373383-57-4 CAPLUS
CN Benzoic acid, 3-chloro-, compd. with 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-2-naphthaleneethanamine N-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 373383-56-3
CMF C27 H31 N O2



CM 2

CRN 535-80-8
CMF C7 H5 Cl O2



RN 373386-73-3 CAPLUS
CN 2-Naphthaleneethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[(4'-methyl[1,1'-biphenyl]-4-yl)methoxy]-, hydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:747736 CAPLUS
DN 135:288594
TI Process for producing amine derivatives
IN Yamashita, Makoto; Kato, Kaneyoshi; Tawada, Hiroyuki
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001074756	A1	20011011	WO 2001-JP2845	20010402
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				JP 2000-105398	A 20000403
	AU 2001044700	A5	20011015	AU 2001-44700	20010402
				JP 2000-105398	A 20000403
				WO 2001-JP2845	W 20010402
	JP 2001348366	A2	20011218	JP 2001-103156	20010402
				JP 2000-105398	A 20000403
	CA 2404736	AA	20021002	CA 2001-2404736	20010402
				JP 2000-105398	A 20000403
				WO 2001-JP2845	W 20010402
	EP 1270545	A1	20030102	EP 2001-917774	20010402
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				JP 2000-105398	A 20000403
				WO 2001-JP2845	W 20010402
	CN 1680280	A	20051012	CN 2005-10059125	20010402
				JP 2000-105398	A 20000403
				CN 2001-807644	A3 20010402

CN 1680332	A	20051012	CN 2005-10059126		20010402
			JP 2000-105398	A	20000403
			CN 2001-807644	A3	20010402
US 2003139602	A1	20030724	US 2002-240574		20021001
US 6784314	B2	20040831			
			JP 2000-105398	A	20000403
			WO 2001-JP2845	W	20010402

OS CASREACT 135:288594; MARPAT 135:288594

AB Described is a process for conveniently and industrially advantageously producing amine derivs. [I; X = (un)substituted hydrocarbyl or cyclic group; R1, R2 = H, (un)substituted C1-6 alkyl; or NR1R2 = (un)substituted N-containing heterocyclyl; ring A = (un)substituted benzene ring; ring B = (un)substituted 4- to 8-membered ring; Y = (un)substituted divalent aliphatic hydrocarbon group] which have effects of inhibiting the secretion and accumulation of amyloid β protein and are useful for the treatment of Alzheimer's disease. (no data). In this process, the ether bond of compds. [II; R = (un)substituted hydrocarbyl; R1, R2, Y, ring A and B = same as above] is selectively cleaved to phenols II (R = H; R1, R2, Y, ring A and B = same as above) without cleaving the amide bond which is present in the same mol. and tertiary amines are not converted into quaternary salts. Selective ether-cleavage reaction is carried out with methionine and methanesulfonic acid. Etherification of the phenols II (R = H; R1, R2, Y, ring A and B = same as above) with X-L (X = same as above; L = leaving group) and reduction of the resulting II (R = X; R1, R2, Y, ring A and B = same as above) gives amines I. This process gives amine derivs. I of good quality in a high yield. Thus, 362.8 g DL-methionine and 546.0 g (+)-N,N-dimethyl-6-methoxy-2-tetralinacetamide were dissolved in 1,638 mL MeSO3H and heated at 110° for 8 h. The reaction liquid was cooled at 10°, successively treated dropwise with 2,730 mL MeOH, cold water 1,092 mL, and cold 25% aqueous NH3 to adjust pH 7.0, and then stirred at 30° for 1 h to give 87.7% (+)-N,N-dimethyl-6-hydroxy-2-tetralinacetamide (III). SOCl2 (177.6 mL) was added dropwise to a solution of 378.6 g 4-hydroxymethyl-1,1'-biphenyl in 1,133 mL DMF and stirred at room temperature for 1.5 h to give, after workup, a DMF solution of 4-chloromethyl-1,1'-biphenyl in 99.1% yield. To the DMF solution were added 435.9 g III, 516.4 g K2CO3, and 436 mL DMF and stirred at 80° for 3 h to give 96.7% (+)-N,N-dimethyl-6-(4-biphenylmethoxy)-2-tetralinacetamide. The latter compound (695 g) was suspended in 3,475 mL PhMe, treated dropwise with a 70% solution (562 g) of sodium dihydrobis(2-methoxyethoxy)aluminate, stirred at room temperature for 1.5 h, treated with 695 mL 1 N aqueous NaOH, and stirred at room temperature for 30 min.

The organic layer was separated, washed twice with 695 mL 1 N aqueous NaOH and twice with 1,390 mL H2O, treated with 348 mL PhMe, heated at 60° and treated with 175 mL 36% aqueous HCl, and stirred under ice-cooling for 1 h. The precipitated crystals were filtered off, washed with 695 mL PhMe and 1,390 mL 50% aqueous MeOH, and vacuum-dried at 40° to give 94.4% (R)-(+)-6-(4-biphenylmethoxy)-2-[2-(N,N-dimethylamino)ethyl]tetralin hydrochloride monohydrate.

IT 365276-12-6P
RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for producing (biphenylmethoxy)[(N,N-dimethylamino)ethyl]tetralin as inhibitor for secretion and accumulation of amyloid β protein by selective ether cleavage reaction with methionine and methanesulfonic acid)

RN 365276-12-6 CAPLUS

CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-

tetrahydro-N,N-dimethyl-, hydrochloride, monohydrate, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

● H_2O

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:228848 CAPLUS
DN 134:266103
TI Preparation of N-tetrahydronaphthalenyl carboxamides as melanin concentrating hormone antagonists
IN Kato, Kaneyoshi; Terauchi, Jun; Mori, Masaaki; Suzuki, Nobuhiro; Shimomura, Yukio; Takekawa, Shiro; Ishihara, Yuji
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001021577	A2	20010329	WO 2000-JP6375	20000919
	WO 2001021577	A3	20011004		
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				JP 1999-266298	A 19990920
				JP 1999-357889	A 19991216
				JP 2000-126272	A 20000420
	CA 2386474	AA	20010329	CA 2000-2386474	20000919
				JP 1999-266298	A 19990920
				JP 1999-357889	A 19991216
				JP 2000-126272	A 20000420
				WO 2000-JP6375	W 20000919

EP 1218336 A2 20020703 EP 2000-961075 20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
JP 1999-266298 A 19990920
JP 1999-357889 A 19991216
JP 2000-126272 A 20000420
WO 2000-JP6375 W 20000919
JP 2002003370 A2 20020109 JP 2000-290357 20000920
JP 1999-266298 A 19990920
JP 1999-357889 A 19991216
JP 2000-126272 A 20000420

OS MARPAT 134:266103

AB The title compds. [I; Ar1 = (un)substituted cyclic group; X = a spacer having a main chain of 1-6 atoms; Y = a bond, a spacer having a main chain of 1-6 atoms; Ar = (un)substituted monocyclic aromatic ring which may be condensed with a 4-8 membered non-aromatic ring; R1, R2 = H, a hydrocarbon group which may have substituents; NR1R2 may form a (un)substituted nitrogen-containing hetero ring; R2 may form a spiro ring together with Ar; R2, together with the adjacent nitrogen atom and Y, may form a (un)substituted nitrogen-containing hetero ring] and their salts, useful as agents for preventing or treating obesity, were prepared and formulated. Thus, reacting 6-amino-2-[(dimethylamino)methyl]tetralin with 4-(4-methoxyphenyl)benzoic acid in the presence of HOBt, WSCD, Et3N and DMAP in DMF afforded the carboxamide II which showed IC50 of 40 nM in GTPgS binding assay.

IT 331758-37-3P 331758-45-3P 331758-46-4P
331758-47-5P 331758-48-6P 331758-49-7P
331758-50-0P 331758-51-1P 331758-52-2P
331758-53-3P 331758-64-6P 331758-75-9P
331758-76-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-tetrahydronaphthalenyl carboxamides as melanin concentrating
hormone antagonists)

RN 331758-37-3 CAPLUS

CN Benzoic acid, 4-methoxy-, 4-[[[(6R)-6-[2-(dimethylamino)ethyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 331758-45-3 CAPLUS

CN Benzoic acid, 4-methoxy-, 4-[[[6-[(dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 331758-46-4 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-6-[[4-[(4-methoxyphenyl)methoxy]phenyl]methoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 331758-47-5 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-[4-[[[6-[(dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 331758-48-6 CAPLUS
CN Benzenesulfonamide, N-[4-[[[6-[(dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 331758-49-7 CAPLUS
CN Benzeneacetamide, N-[4-[[[6-[(dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 331758-50-0 CAPLUS
CN Benzamide, N-[4-[[[6-[(dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 331758-51-1 CAPLUS
CN Benzamide, N-[4-[[[6-[(dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 331758-52-2 CAPLUS
CN Benzamide, N-[4-[[[6-[(dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 331758-53-3 CAPLUS
CN Benzamide, N-[4-[[[6-[(dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]phenyl]-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 331758-64-6 CAPLUS
CN Phenol, 4-[[[(6R)-6-[2-(dimethylamino)ethyl]-5,6,7,8-tetrahydro-2-

naphthalenyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 331758-75-9 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[(4-nitrophenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 331758-76-0 CAPLUS
CN 2-Naphthalenemethanamine, 6-[(4-aminophenyl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:790466 CAPLUS
DN 133:350058
TI Preparation of 6-[[(aryl and heteroaryl)oxy]methyl]naphthalene-2-carboximidamide derivatives and their antithrombotic activity
IN Alcouffe, Chantal; Bellevergue, Patrice; Dellac, Genevieve; Latham, Christopher; Lassalle, Gilbert; Mallart, Sergio; Martin, Valerie; Masson, Christine; Mccort, Gary
PA Sanofi-Synthelabo, Fr.
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066545	A1	20001109	WO 2000-FR1087	20000425

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

				FR 1999-5632	A	19990504
FR 2793247	A1	20001110		FR 1999-5632		19990504
FR 2793247	B1	20010622				
CA 2371284	AA	20001109		CA 2000-2371284		20000425
				FR 1999-5632	A	19990504
				WO 2000-FR1087	W	20000425
EP 1177169	A1	20020206		EP 2000-922738		20000425
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO						
				FR 1999-5632	A	19990504
				WO 2000-FR1087	W	20000425
BR 2000010230	A	20020213		BR 2000-10230		20000425
				FR 1999-5632	A	19990504
				WO 2000-FR1087	W	20000425
TR 200103215	T2	20020722		TR 2001-3215		20000425
				FR 1999-5632	A	19990504
JP 2002543176	T2	20021217		JP 2000-615376		20000425
				FR 1999-5632	A	19990504
				WO 2000-FR1087	W	20000425
EE 200100579	A	20030217		EE 2001-579		20000425
				FR 1999-5632	A	19990504
				WO 2000-FR1087	W	20000425
BG 106048	A	20020531		BG 2001-106048		20011024
				FR 1999-5632	A	19990504
				WO 2000-FR1087	W	20000425
ZA 2001008758	A	20021024		ZA 2001-8758		20011024
				FR 1999-5632	A	19990504
NO 2001005387	A	20020107		NO 2001-5387		20011102
				FR 1999-5632	A	19990504
				WO 2000-FR1087	W	20000425

OS MARPAT 133:350058

AB The title compds. I [R1 = H, amino, C1-C4 alkyl, C1-C6 alkoxycarbonyl, OH; R2 = C1-C6 alkyl, Ph, benzyl, CH2Q wherein Q is a heterocyclic group; R3 and R5 = H, C1-C4 alkyl, COOH; R4 = H, C1-C4 alkyl, (CH2)pCOOR8; Z = CH, N], antithrombotic agents, were prepared E.g., 6-[[[8-[[[(thiazol-4-ylmethyl)sulfonyl]amino]methyl]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]methyl]naphthalene-2-carboximidamide hydrochloride was prepared

IT 305797-04-0P 305797-09-5P 305797-10-8P
305797-13-1P 305797-14-2P 305797-21-1P
305797-22-2P 305797-24-4P 305797-28-8P
305797-33-5P 305797-34-6P 305797-37-9P
305797-38-0P 305797-42-6P 305797-44-8P
305797-47-1P 305797-59-5P 305798-18-9P
305798-19-0P 305813-97-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antithrombotic activity of [[(aryl- and heteroaryl)oxy]methyl]naphthalenecarboximidamide derivs.)

RN 305797-04-0 CAPLUS

CN 2-Naphthalenecarboximidamide, 6-[[[5,6,7,8-tetrahydro-8-[2-[[(phenylmethyl)sulfonyl]amino]ethyl]-2-naphthalenyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 305797-09-5 CAPLUS
CN Benzeneacetamide, N-[[7-[[6-(aminoiminomethyl)-2-naphthalenyl]methoxy]-1,2,3,4-tetrahydro-1-naphthalenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 305797-10-8 CAPLUS
CN 2-Naphthalenecarboximidamide, 6-[[[5,6,7,8-tetrahydro-8-[[[(2,2,2-trifluoroethyl)sulfonyl]amino]methyl]-2-naphthalenyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 305797-13-1 CAPLUS
CN 2-Naphthalenecarboximidamide, 6-[[[5,6,7,8-tetrahydro-8-[[[[[(3-

methoxyphenyl)methyl]amino]carbonyl]amino]methyl]-2-
naphthalenyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 305797-14-2 CAPLUS
CN 2-Naphthalenecarboximidamide, 6-[[[5,6,7,8-tetrahydro-8-[[[[(3-
methoxyphenyl)methyl]sulfonyl]amino]methyl]-2-naphthalenyl]oxy]methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



RN 305797-21-1 CAPLUS
CN 2-Naphthalenecarboximidamide, 6-[[[5,6,7,8-tetrahydro-8-[[[(4,4,4-
trifluorobutyl)sulfonyl]amino]methyl]-2-naphthalenyl]oxy]methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 305797-22-2 CAPLUS
CN Benzeneacetamide, N-[[7-[[6-(aminoiminomethyl)-2-naphthalenyl]methoxy]-1,2,3,4-tetrahydro-1-naphthalenyl]methyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 305797-24-4 CAPLUS
CN Benzoic acid, 3-[[[[[7-[[6-(aminoiminomethyl)-2-naphthalenyl]methoxy]-1,2,3,4-tetrahydro-1-naphthalenyl]methyl]amino]sulfonyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 305797-28-8 CAPLUS
CN 2-Naphthalenecarboximidamide, 6-[[[5,6,7,8-tetrahydro-8-[[[(3-pyridinylmethyl)sulfonyl]amino]methyl]-2-naphthalenyl]oxy]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 305797-33-5 CAPLUS
CN 2-Naphthalenecarboximidamide, 6-[[[5,6,7,8-tetrahydro-8-[[[(4-thiazolylmethyl)sulfonyl]amino]methyl]-2-naphthalenyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 305797-34-6 CAPLUS
CN 2-Naphthalenecarboximidamide, 6-[[[5,6,7,8-tetrahydro-8-[[[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]amino]methyl]-2-naphthalenyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 305797-37-9 CAPLUS
CN 2-Naphthalenecarboximidamide, 6-[[[5,6,7,8-tetrahydro-8-[[[[[3-(trifluoromethoxy)phenyl]methyl]sulfonyl]amino]methyl]-2-naphthalenyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 305797-38-0 CAPLUS
CN 2-Naphthalenecarboximidamide, 6-[[[5,6,7,8-tetrahydro-8-[[[(3,3,3-trifluoropropyl)sulfonyl]amino]methyl]-2-naphthalenyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 305797-42-6 CAPLUS
CN 2-Naphthalenecarboximidamide, 6-[[[8-[[[[[3-(dimethylamino)phenyl]methyl]sulfonyl]amino]methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 305797-44-8 CAPLUS
CN 2-Naphthalenecarboximidamide, 6-[[[8-[[[[[4-(dimethylamino)phenyl]methyl]sulfonyl]amino]methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

●2 HCl

RN 305797-47-1 CAPLUS
CN Benzoic acid, 4-[[[[[7-[[6-(aminoiminomethyl)-2-naphthalenyl]methoxy]-

1,2,3,4-tetrahydro-1-naphthalenyl]methyl]amino]sulfonyl]methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



RN 305797-59-5 CAPLUS
CN 2-Naphthalenecarboximidamide, 6-[[[8-[[[[(3-fluorophenyl)methyl]sulfonyl]amino]methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



RN 305798-18-9 CAPLUS
CN Benzoic acid, 3-[[[[[1,2,3,4-tetrahydro-7-[[6-[(hydroxyamino)iminomethyl]-2-naphthalenyl]methoxy]-1-naphthalenyl]methyl]amino]sulfonyl]methyl]-,
methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● HCl

RN 305798-19-0 CAPLUS
CN Benzoic acid, 3-[[[[[1,2,3,4-tetrahydro-7-[[6-[(hydroxyamino)iminomethyl]-2-naphthalenyl]methoxy]-1-naphthalenyl]methyl]amino]sulfonyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 305813-97-2 CAPLUS
CN ar-Naphthalenecarboxylic acid, 2-[[6-(aminoiminomethyl)-2-

naphthalenyl]methoxy]-8-[[[[(3-fluorophenyl)methyl]sulfonyl]amino]methyl]-5,6,7,8-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



D1—CO2H

IT 305797-87-9P 305797-88-0P 305797-90-4P
305797-91-5P 305797-98-2P 305798-11-2P
305798-12-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and antithrombotic activity of [[(aryl- and heteroaryl)oxy]methyl]naphthalenecarboximidamide derivs.)

RN 305797-87-9 CAPLUS
CN Carbamic acid, [[7-[(6-cyano-2-naphthalenyl)methoxy]-1,2,3,4-tetrahydro-1-naphthalenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 305797-88-0 CAPLUS
CN 2-Naphthalenecarbonitrile, 6-[[[8-(aminomethyl)-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 305797-90-4 CAPLUS
CN 4-Thiazolemethanesulfonamide, N-[[7-[(6-cyano-2-naphthalenyl)methoxy]-1,2,3,4-tetrahydro-1-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 305797-91-5 CAPLUS
CN 2-Naphthalenecarboximidamide, N-hydroxy-6-[[[5,6,7,8-tetrahydro-8-[[[(4-thiazolylmethyl)sulfonyl]amino]methyl]-2-naphthalenyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 305797-98-2 CAPLUS
CN Benzenemethanesulfonamide, N-[[7-[(6-cyano-2-naphthalenyl)methoxy]-1,2,3,4-tetrahydro-1-naphthalenyl]methyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 305798-11-2 CAPLUS
CN Benzoic acid, 3-[[[[[7-[(6-cyano-2-naphthalenyl)methoxy]-1,2,3,4-tetrahydro-1-naphthalenyl]methyl]amino]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 305798-12-3 CAPLUS
CN Benzoic acid, 3-[[[[[7-[(6-cyano-2-naphthalenyl)methoxy]-1,2,3,4-tetrahydro-1-naphthalenyl]methyl]amino]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:117017 CAPLUS
DN 132:166509
TI Preparation of aminomethylcarboxylic acid derivatives for treatment of CNS disorders
IN Gibson, Samuel George; Jaap, David Robert; Thorn, Simon Nicholas; Gilfillan, Robert
PA Akzo Nobel N.V., Neth.
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2000007978	A1	20000217	WO 1999-EP5477		19990726
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, TJ, TM					
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
				EP 1998-306149	A	19980731
	TW 555757	B	20031001	TW 1999-88112566		19990723
				EP 1998-306149	A	19980731
	CA 2337041	AA	20000217	CA 1999-2337041		19990726
				EP 1998-306149	A	19980731
				WO 1999-EP5477	W	19990726
	AU 9953724	A1	20000228	AU 1999-53724		19990726
	AU 762759	B2	20030703			
				EP 1998-306149	A	19980731
				WO 1999-EP5477	W	19990726
	BR 9912621	A	20010424	BR 1999-12621		19990726
				EP 1998-306149	A	19980731
				WO 1999-EP5477	W	19990726
	TR 200100270	T2	20010521	TR 2001-200100270		19990726
				EP 1998-306149	A	19980731
	EP 1100769	A1	20010523	EP 1999-939419		19990726

EP 1100769		B1	20021204			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI						
				EP 1998-306149	A	19980731
				WO 1999-EP5477	W	19990726
JP 2002522412		T2	20020723	JP 2000-563613		19990726
				EP 1998-306149	A	19980731
				WO 1999-EP5477	W	19990726
AT 228995		E	20021215	AT 1999-939419		19990726
				EP 1998-306149	A	19980731
				WO 1999-EP5477	W	19990726
PT 1100769		T	20030430	PT 1999-939419		19990726
				EP 1998-306149	A	19980731
NZ 509568		A	20030530	NZ 1999-509568		19990726
				EP 1998-306149	A	19980731
				WO 1999-EP5477	W	19990726
ES 2189462		T3	20030701	ES 1999-939419		19990726
				EP 1998-306149	A	19980731
RU 2225389		C2	20040310	RU 2001-105536		19990726
				EP 1998-306149	A	19980731
				WO 1999-EP5477	W	19990726
US 6410592		B1	20020625	US 2001-744520		20010125
				EP 1998-306149	A	19980731
				WO 1999-EP5477	W	19990726
NO 2001000514		A	20010130	NO 2001-514		20010130
				EP 1998-306149	A	19980731
				WO 1999-EP5477	W	19990726
HK 1035525		A1	20030411	HK 2001-106227		20010904
				EP 1998-306149	A	19980731
				WO 1999-EP5477	W	19990726

OS MARPAT 132:166509

AB Aminomethylcarboxylic acid derivs. I [Z = (CH2)n, O, S, SO, SO2 or NR5; n = 0, 1 or 2; X represents 1-3 substituents independently selected from H, halogen, (C1-6)alkyloxy, (C3-6)cycloalkyloxy, (C6-12)aryloxy, (C6-12)aryl, thienyl, SR6, SOR6, SO2R6, NR62, NHR6, NH2, NHCOR6, NSO2R6, CN, CO2R6 and (C1-4)alkyl, optionally substituted with halogen, (C6-12)aryl, (C1-6)alkyloxy or (C6-12)aryloxy; or 2 substituents at adjacent positions together represent a fused (C5-6)aryl group, a fused (C5-6)cycloalkyl ring or O(CH2)mO; m = 1 or 2; Y represents 1-3 substituents independently selected from H, halogen, (C1-4)alkyloxy, SR6, NR62 and (C1-4)alkyl, optionally substituted with halogen; R1 = CO2R7 or CONR8R9; R2 and R6 are (C1-4)alkyl; R3, R4 and R5 are independently H or (C1-4)alkyl; R7, R8 and R9 are independently H, (C1-4)alkyl, (C6-12)aryl or arylalkyl] or a pharmaceutically acceptable salt were prepared for use in therapy, more specifically for the treatment of CNS disorders. Thus, (-)-lithium cis-N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylate was prepared and showed pIC50 = 6.8 for selective inhibition of glycine transport by the human glyT-1b transporter as compared to the human GlyT-2 transporter.

IT 258887-03-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminomethylcarboxylic acid derivs. for treatment of CNS disorders)

RN 258887-03-5 CAPLUS

CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-N-methyl-1-phenyl-6-(phenylmethoxy)-, hydrochloride, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:716155 CAPLUS
DN 131:310459
TI Method for preparation of optical isomers of tetralin-2-acetamide and 2-(2-aminoethyl)tetralin derivatives and their analogs
IN Kawata, Mitsuru; Yamano, Toru; Yamashita, Saneyuki; Terauchi, Atsushi
PA Takeda Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	JP 11310561	A2	19991109	JP 1998-202583		19980717
				JP 1997-193496	A	19970718
				JP 1998-44768	A	19980226

OS CASREACT 131:310459; MARPAT 131:310459
AB The title compds. [I; ring A = (un)substituted aromatic ring; X = CH2CH2, (CH2)3, OCH2CH2, OCH2, NR1CH2, NR1CH2CH2; wherein R1 = H, alkyl, alkylcarbonyl, alkoxycarbonyl; m = 1-3; T = hydroxyacyl], which are useful as intermediates for remedies or preventives for Alzheimer's disease and inhibitors of production and secretion of amyloid β protein, are prepared by asym. hydrogenation of dihydronaphthalene-2-acetamide derivs. and their analogs (II; ring A, X, m, T = same as above) in the presence of an optically active transition metal-phosphine complex. Thus, a solution of 18.3 g N,N-dimethyl-2-(6-methoxy-3,4-dihydronaphthalen-2-yl)acetamide (preparation given) and 1.24 g [RuCl2[(R)-BINAP]]2NEt3 in 160 mL ethanol was hydrogenated at 70° and H pressure 100 kg/cm2 for 6 h to give 15.5 g (-)-N,N-dimethyl-2-(6-methoxytetralin-2-yl)acetamide of 98.3% ee.
IT 212571-54-5P 212571-55-6P 212571-88-5P
212571-91-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of optical isomers of tetralinacetamide and (aminoethyl)tetralin derivs. by asym. hydrogenation of dihydronaphthaleneacetamide and (aminoethyl)dihydronaphthalene derivs.)
RN 212571-54-5 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 212571-55-6 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



● HCl

RN 212571-88-5 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-N,N-diethyl-1,2,3,4-tetrahydro-, hydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 212571-91-0 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-N,N-diethyl-1,2,3,4-tetrahydro-, hydrochloride, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



L4 ANSWER 13 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:608594 CAPLUS
DN 129:216428
TI Preparation of 2-aminoalkylteralines as amyloid-β production inhibitors
IN Kato, Kaneyoshi; Terauchi, Jun; Fukumoto, Hiroaki; Kakihana, Mitsuru
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 238 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9838156	A1	19980903	WO 1998-JP780	19980226
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				JP 1997-43940	A 19970227
				JP 1997-193497	A 19970718
	CA 2276278	AA	19980903	CA 1998-2276278	19980226
				JP 1997-43940	A 19970227
				JP 1997-193497	A 19970718
				WO 1998-JP780	W 19980226
	AU 9861166	A1	19980918	AU 1998-61166	19980226
				JP 1997-43940	A 19970227
				JP 1997-193497	A 19970718
				WO 1998-JP780	W 19980226
	JP 11080098	A2	19990323	JP 1998-44769	19980226
				JP 1997-43940	A 19970227
				JP 1997-193497	A 19970718
	EP 971878	A1	20000119	EP 1998-905656	19980226
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				JP 1997-43940	A 19970227
				JP 1997-193497	A 19970718
				WO 1998-JP780	W 19980226
	JP 2003113147	A2	20030418	JP 2002-264457	19980226
				JP 1997-43940	A 19970227

			JP 1997-193497	A	19970718
			JP 1998-44769	A3	19980226
US 6310107	B1	20011030	US 1999-331460		19990621
			JP 1997-43940	A	19970227
			JP 1997-193497	A	19970718
			WO 1998-JP780	W	19980226
US 2002032189	A1	20020314	US 2001-931140		20010816
US 6613805	B2	20030902			
			JP 1997-43940	A	19970227
			JP 1997-193497	A	19970718
			US 1999-331460	A3	19990621
US 2004077867	A1	20040422	US 2003-645934		20030821
			JP 1997-43940	A	19970227
			JP 1997-193497	A	19970718
			WO 1998-JP780	A	19980226
			US 2001-931140	A3	20010816

OS MARPAT 129:216428

AB The title compds. [I; Ar = (un)substituted aromatic ring, fused aromatic group; X = a bond, S, SO, SO2, etc.; Y = (un)substituted divalent C1-6 aliphatic hydrocarbon group optionally containing O or S; R1, R2 = H, lower alkyl; NR1R2 = (un)substituted N-containing heterocyclic ring; Ring A = (un)substituted benzene; Ring B = (un)substituted 4-8 membered ring] and their salts, which have the effect of inhibiting amyloid-β protein production and/or secretion and are useful for preventing and/or treating the neurodegenerative disease such as Alzheimer's disease, were prepared and formulated. Thus, treatment of [6-(4-biphenylyl)methoxy-2-tetralin]-N,N-dimethylacetamide with LiAlH4 in THF afforded II.HCl which showed 74% and 75% inhibition of the production and/or secretion of Aβ1-40 and Aβ1-42, resp.

IT 212570-95-1P 212570-98-4P 212571-00-1P
212571-03-4P 212571-05-6P 212571-08-9P
212571-13-6P 212571-17-0P 212571-18-1P
212571-23-8P 212571-24-9P 212571-25-0P
212571-26-1P 212571-27-2P 212571-28-3P
212571-29-4P 212571-30-7P 212571-31-8P
212571-32-9P 212571-34-1P 212571-35-2P
212571-36-3P 212571-37-4P 212571-39-6P
212571-40-9P 212571-41-0P 212571-42-1P
212571-43-2P 212571-44-3P 212571-45-4P
212571-50-1P 212571-51-2P 212571-52-3P
212571-54-5P 212571-55-6P 212571-56-7P
212571-57-8P 212571-58-9P 212571-59-0P
212571-60-3P 212571-61-4P 212571-62-5P
212571-63-6P 212571-64-7P 212571-65-8P
212571-66-9P 212571-67-0P 212571-68-1P
212571-69-2P 212571-70-5P 212571-71-6P
212571-74-9P 212571-79-4P 212571-82-9P
212571-83-0P 212571-84-1P 212571-85-2P
212571-88-5P 212571-91-0P 212573-57-4P
212573-58-5P 212573-59-6P 212573-60-9P
212573-61-0P 212573-62-1P 212573-63-2P
212573-64-3P 212573-65-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-aminoalkyltetralines as amyloid-β production inhibitors)

RN 212570-95-1 CAPLUS

CN 2-Naphthalenemethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212570-98-4 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-(2-naphthalenylmethoxy)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-00-1 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[[6-[(dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-03-4 CAPLUS
CN 2-Naphthalenemethanamine, 7-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-05-6 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-7-(2-naphthalenylmethoxy)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-08-9 CAPLUS
CN 2-Naphthalenemethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-13-6 CAPLUS
CN 2-Naphthalenemethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dipropyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-17-0 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-18-1 CAPLUS
CN 2-Naphthaleneethanamine, 1,2,3,4-tetrahydro-6-(2-naphthalenylmethoxy)-N,N-dipropyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-23-8 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-6-[(4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-24-9 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[(4'-methyl[1,1'-biphenyl]-4-yl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-25-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxaldehyde, 4'-[[[6-[(dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-26-1 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[[4'-(methylthio)[1,1'-biphenyl]-4-yl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-27-2 CAPLUS
CN 2-Naphthalenemethanamine, 6-[(4'-fluoro[1,1'-biphenyl]-4-yl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-28-3 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[(3'-nitro[1,1'-biphenyl]-4-yl)methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-29-4 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-6-[(3'-methoxy[1,1'-biphenyl]-4-yl)methoxy]-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-30-7 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-6-[(2'-methoxy[1,1'-biphenyl]-4-yl)methoxy]-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-31-8 CAPLUS
CN 2-Naphthalenemethanamine, 6-[[3',5'-bis(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-32-9 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[[4-(3-thienyl)phenyl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-34-1 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[[4-(2-thienyl)phenyl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-35-2 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[[4-(3-pyridinyl)phenyl]methoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 212571-36-3 CAPLUS
CN 2-Naphthalenemethanamine, 6-([1,1'-biphenyl]-3-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-37-4 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-6-[(4'-methoxy[1,1'-biphenyl]-3-yl)methoxy]-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-39-6 CAPLUS
CN 2-Naphthalenemethanamine, 6-[(4'-fluoro[1,1'-biphenyl]-3-yl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-40-9 CAPLUS
CN 2-Naphthalenemethanamine, 6-([1,1'-biphenyl]-2-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-41-0 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-6-[(4'-methoxy[1,1'-biphenyl]-2-yl)methoxy]-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-42-1 CAPLUS
CN 2-Naphthalenemethanamine, 6-[(4'-fluoro[1,1'-biphenyl]-2-yl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-43-2 CAPLUS
CN 2-Naphthalenemethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-N-ethyl-1,2,3,4-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-44-3 CAPLUS
CN 2-Naphthalenemethanamine, 6-[(4'-ethyl[1,1'-biphenyl]-4-yl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-45-4 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-N,N-diethyl-1,2,3,4-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-50-1 CAPLUS
CN 2-Naphthaleneethanamine, 6-[(3'-amino[1,1'-biphenyl]-4-yl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 212571-51-2 CAPLUS
CN 2-Naphthaleneethanamine, 1,2,3,4-tetrahydro-6-[(4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-52-3 CAPLUS
CN 2-Naphthalenepropanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-54-5 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 212571-55-6 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



● HCl

RN 212571-56-7 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 212571-57-8 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 212571-58-9 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, (-)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 212571-57-8
CMF C27 H31 N O

Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 212571-59-0 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-, (-)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 212571-57-8
CMF C27 H31 N O

Rotation (-).



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 212571-60-3 CAPLUS
CN 2-Naphthaleneethanamine, 1,2,3,4-tetrahydro-6-[(4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]-N,N-dimethyl-, hydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 212571-61-4 CAPLUS
CN 2-Naphthaleneethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[(4'-methyl[1,1'-biphenyl]-4-yl)methoxy]-, hydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 212571-62-5 CAPLUS
CN 2-Naphthaleneethanamine, 6-[(3'-amino[1,1'-biphenyl]-4-yl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, dihydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● 2 HCl

RN 212571-63-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxaldehyde, 4'-[[[6-[2-(dimethylamino)ethyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]-, hydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 212571-64-7 CAPLUS
CN Acetamide, N-[4'-[[[6-[2-(dimethylamino)ethyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl][1,1'-biphenyl]-3-yl]-, monohydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 212571-65-8 CAPLUS
CN 2-Naphthaleneethanamine, 6-[(2',4'-dimethoxy[1,1'-biphenyl]-4-yl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 212571-66-9 CAPLUS
CN 2-Naphthaleneethanamine, 6-[(3',4'-dimethoxy[1,1'-biphenyl]-4-yl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 212571-67-0 CAPLUS
CN 2-Naphthaleneethanamine, 6-[[4-(1,3-benzodioxol-5-yl)phenyl]methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 212571-68-1 CAPLUS
CN 2-Naphthaleneethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[(2',3',4'-trimethoxy-6'-methyl[1,1'-biphenyl]-4-yl)methoxy]-, hydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 212571-69-2 CAPLUS
CN 2-Naphthaleneethanamine, 6-[[4-(2-benzofuranyl)phenyl]methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 212571-70-5 CAPLUS
CN 2-Naphthaleneethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[[4-(2-naphthalenyl)phenyl]methoxy]-, hydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 212571-71-6 CAPLUS
CN 2-Naphthaleneethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[(4'-methyl[1,1'-biphenyl]-4-yl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-74-9 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-79-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[[6-[2-(dimethylamino)ethyl]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-82-9 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N-methyl- (9CI) (CA INDEX NAME)



RN 212571-83-0 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-84-1 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-N-ethyl-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 212571-85-2 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-N-ethyl-1,2,3,4-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212571-88-5 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-N,N-diethyl-1,2,3,4-tetrahydro-, hydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 212571-91-0 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-N,N-diethyl-1,2,3,4-tetrahydro-, hydrochloride, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



● HCl

RN 212573-57-4 CAPLUS

CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 212573-58-5 CAPLUS
CN 2-Naphthalenemethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 212573-59-6 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-6-[(4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 212573-60-9 CAPLUS
CN 2-Naphthaleneethanamine, 6-([1,1'-biphenyl]-4-ylmethoxy)-N,N-diethyl-1,2,3,4-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 212573-61-0 CAPLUS
CN 2-Naphthaleneethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[(4'-methyl[1,1'-biphenyl]-4-yl)methoxy]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 212573-62-1 CAPLUS
CN 2-Naphthaleneethanamine, 1,2,3,4-tetrahydro-6-[(4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]-N,N-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 212573-63-2 CAPLUS
CN 2-Naphthaleneethanamine, 6-[(2',4'-dimethoxy[1,1'-biphenyl]-4-yl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 212573-64-3 CAPLUS
CN 2-Naphthaleneethanamine, 6-[[4-(1,3-benzodioxol-5-yl)phenyl]methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 212573-65-4 CAPLUS
CN 2-Naphthaleneethanamine, 6-[(3',4'-dimethoxy[1,1'-biphenyl]-4-yl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



IT 212573-48-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-aminoalkyltetralines as amyloid-β production inhibitors)
RN 212573-48-3 CAPLUS
CN 2-Naphthaleneethanamine, 6-[(4-bromophenyl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT 212572-52-6P 212572-62-8P 212572-63-9P
212572-64-0P 212572-66-2P 212572-68-4P
212572-70-8P 212572-73-1P 212572-92-4P
212573-07-4P 212573-38-1P 212573-39-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-aminoalkyltetralines as amyloid-β production inhibitors)
RN 212572-52-6 CAPLUS

CN Acetamide, N-[[6-([1,1'-biphenyl]-4-ylmethoxy)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 212572-62-8 CAPLUS
CN 2-Naphthalenemethanamine, 6-[(4-bromophenyl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 212572-63-9 CAPLUS
CN 2-Naphthalenemethanamine, 6-[(3-bromophenyl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 212572-64-0 CAPLUS
CN 2-Naphthalenemethanamine, 6-[(2-bromophenyl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 212572-66-2 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-(phenylmethoxy)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212572-68-4 CAPLUS
CN 2-Naphthalenemethanamine, 6-[(2-chlorophenyl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212572-70-8 CAPLUS
CN 2-Naphthalenemethanamine, 6-[(2,4-dichlorophenyl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212572-73-1 CAPLUS
CN 2-Naphthalenemethanamine, 1,2,3,4-tetrahydro-N,N-dimethyl-6-[[4-(phenylmethoxy)phenyl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212572-92-4 CAPLUS
CN 2-Naphthaleneethanamine, 6-[(4-bromophenyl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 212573-07-4 CAPLUS
CN 2-Naphthaleneethanamine, 6-[(4-bromophenyl)methoxy]-1,2,3,4-tetrahydro-N,N-dimethyl-, hydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



● HCl

RN 212573-38-1 CAPLUS
CN Benzoic acid, 3-chloro-, compd. with 6-([1,1'-biphenyl]-4-ylmethoxy)-2-[2-(dimethylamino)ethyl]-3,4-dihydro-1(2H)-naphthalenone (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 212573-37-0
CMF C27 H29 N O2



CM 2

CRN 535-80-8
CMF C7 H5 Cl O2



RN 212573-39-2 CAPLUS
CN 1(2H)-Naphthalenone, 6-([1,1'-biphenyl]-4-ylmethoxy)-2-[2-(diethylamino)ethyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:603193 CAPLUS
DN 129:216420
TI Preparation of tetralone derivatives as antiarrhythmic agents
IN Ahmad, Saleem; Stein, Philip D.; Ferrara, Francis N.; Atwal, Karnail S.
PA Bristol-Myers Squibb Co., USA
SO PCT Int. Appl., 204 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI WO 9836749	A1	19980827	WO 1998-US2338		19980207
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
			US 1997-38917P	P	19970221
US 6048877	A	20000411	US 1998-9812		19980120
			US 1997-38917P	P	19970221
AU 9861486	A1	19980909	AU 1998-61486		19980207
			US 1997-38917P	P	19970221
			WO 1998-US2338	W	19980207

OS MARPAT 129:216420
AB The title compds. [I; R1 = halo, alkyl, alkenyl, etc.; R2 = H, alkyl, halo, etc.; R3 = O, OH, alkoxy, etc.; R4 = H, alkyl, alkyl(COalkyl),

alkyl(COOalkyl); R3R4 taken together with the atoms to which they are attached form a 5-7 membered ring containing up to three heteroatoms selected from O, N and S; R5 = H, alkyl, alkenyl, etc.; n = 0-2], useful in the treatment of arrhythmia, were prepared Thus, treatment of 6-methoxytetralone with paraformaldehyde and N-methylanilinium trifluoroacetate in THF followed by reaction of the resulting 2-methylene-6-methoxy-1-tetralone with 4-phenylpiperidine over alumina in PhMe afforded the title compound II. Compds. I are effective at 0.001-10 mg/kg/day.

IT 212256-67-2P 212256-68-3P 212256-69-4P
212256-99-0P 212257-04-0P 212257-07-3P
212257-10-8P 212257-12-0P 212257-15-3P
212257-18-6P 212257-21-1P 212257-22-2P
212257-23-3P 212257-78-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetralones as antiarrhythmic agents)

RN 212256-67-2 CAPLUS
CN 1-Naphthalenol, 6-([1,1'-biphenyl]-2-ylmethoxy)-1,2,3,4-tetrahydro-2-[[[(1S)-1-phenylethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212256-68-3 CAPLUS
CN 1-Naphthalenol, 6-([1,1'-biphenyl]-2-ylmethoxy)-1,2,3,4-tetrahydro-2-[[[(1S)-1-phenylethyl]amino]methyl]-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212256-69-4 CAPLUS
CN 1-Naphthalenol, 6-([1,1'-biphenyl]-2-ylmethoxy)-1,2,3,4-tetrahydro-2-[[[(1S)-1-phenylethyl]amino]methyl]-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212256-99-0 CAPLUS
CN 1-Naphthalenol, 2-[2-[bis(2-methylpropyl)amino]ethyl]-1,2,3,4-tetrahydro-6-(phenylmethoxy)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 212257-04-0 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-6-(phenylmethoxy)-2-[2-[(phenylmethyl)amino]ethyl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 212257-07-3 CAPLUS
CN 1-Naphthalenol, 6-([1,1'-biphenyl]-2-ylmethoxy)-1,2,3,4-tetrahydro-2-[2-[[(1S)-1-phenylethyl]amino]ethyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 212257-06-2
CMF C33 H35 N O2

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 212257-10-8 CAPLUS
CN 1-Naphthalenol, 6-([1,1'-biphenyl]-2-ylmethoxy)-1,2,3,4-tetrahydro-2-[2-[[(1R)-1-phenylethyl]amino]ethyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 212257-09-5
CMF C33 H35 N O2

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 212257-12-0 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[2-[[(1R)-1-phenylethyl]amino]ethyl]-6-(phenylmethoxy)-, (1S,2S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 212257-11-9
CMF C27 H31 N O2

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 212257-15-3 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[2-[[(1R)-1-phenylethyl]amino]ethyl]-6-(phenylmethoxy)-, (1R,2R)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 212257-14-2
CMF C27 H31 N O2

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 212257-18-6 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[2-[[(1S)-1-phenylethyl]amino]ethyl]-6-(phenylmethoxy)-, (1S,2S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 212257-17-5
CMF C27 H31 N O2

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 212257-21-1 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[2-[[(1S)-1-phenylethyl]amino]ethyl]-6-(phenylmethoxy)-, (1R,2R)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 212257-20-0
CMF C27 H31 N O2

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 212257-22-2 CAPLUS
CN 1-Naphthalenol, 6-([1,1'-biphenyl]-2-ylmethoxy)-1,2,3,4-tetrahydro-2-[2-[[(1S)-1-phenylethyl]amino]ethyl]-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212257-23-3 CAPLUS
CN 1-Naphthalenol, 6-([1,1'-biphenyl]-2-ylmethoxy)-1,2,3,4-tetrahydro-2-[2-[[(1S)-1-phenylethyl]amino]ethyl]-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212257-78-8 CAPLUS
CN 1(2H)-Naphthalenone, 2-[2-[bis(1-methylethyl)amino]ethyl]-3,4-dihydro-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:513495 CAPLUS
DN 125:167594
TI Preparation of naphthyloxyacetates and analogs as PGE2 receptor ligands
IN Nagao, Yuuki; Torisu, Kazuhiko; Maruyama, Takayuki
PA Ono Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 143 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 719760	A1	19960703	EP 1995-309493	19951228
	EP 719760	B1	19990922		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				JP 1994-337651 A	19941228
	US 5753700	A	19980519	US 1995-574133	19951218
				JP 1994-337651 A	19941228
	JP 08239356	A2	19960917	JP 1995-350873	19951225
				JP 1994-337651 A	19941228
	AT 184871	E	19991015	AT 1995-309493	19951228
				JP 1994-337651 A	19941228
	ES 2140629	T3	20000301	ES 1995-309493	19951228
				JP 1994-337651 A	19941228
	US 6013673	A	20000111	US 1998-12448	19980123
				JP 1994-337651 A	19941228
				US 1995-574133 A3	19951218
	GR 3031808	T3	20000229	GR 1999-402901	19991110
				JP 1994-337651 A	19941228

OS MARPAT 125:167594
AB Title compds. [I; R = Z1Z2R2; R1 = H, (hydroxy)alkyl, carboxyalkyl, etc.; R2 = (un)substituted alk(en)yl, NPh2, etc.; Z1 = bond, alk(en)ylene(oxy),

etc.; Z2 = NR3CO or CONR3; R3 = H or alkyl] were prepared Thus, tert-Bu 5-hydroxynaphthalene-1-propionate was etherified by BrCH2CO2Me and the saponified product amidated by HNPh2 to give, after saponification, title compound II which had Ki of 0.011μM for inhibition of PGE2 binding at mouse CHO cell preparation in vitro.

IT 180198-07-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of naphthyloxyacetates and analogs as PGE2 receptor ligands)

RN 180198-07-6 CAPLUS

CN Benzeneacetamide, α-phenyl-N-[2-[5-(phenylmethoxy)-1-naphthalenyl]ethyl]- (9CI) (CA INDEX NAME)



IT 180197-84-6, 5-Benzyloxy-1-Naphthaleneethanamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of naphthyloxyacetates and analogs as PGE2 receptor ligands)

RN 180197-84-6 CAPLUS

CN 1-Naphthaleneethanamine, 5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:478078 CAPLUS

DN 122:239346

TI Preparation of 4a-(aminoethyl)octahydrophenanthren-8a-ols as NMDA antagonists.

IN Godel, Thierry; Gutknecht, Eva-Maria

PA F. Hoffmann-la Roche AG, Switz.

SO Eur. Pat. Appl., 40 pp.
CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 606661	A1	19940720	EP 1993-121161	19931231

EP 606661	B1	19970312				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE						
			CH 1993-123	A	19930115	
CA 2111138	AA	19940716	CA 1993-2111138		19931210	
			CH 1993-123	A	19930115	
AT 150001	E	19970315	AT 1993-121161		19931231	
			CH 1993-123	A	19930115	
ES 2099362	T3	19970516	ES 1993-121161		19931231	
			CH 1993-123	A	19930115	
ZA 9400103	A	19940819	ZA 1994-103		19940107	
			CH 1993-123	A	19930115	
AU 9453114	A1	19940721	AU 1994-53114		19940110	
AU 668442	B2	19960502				
			CH 1993-123	A	19930115	
HU 69688	A2	19950928	HU 1994-56		19940110	
			CH 1993-123	A	19930115	
JP 06234711	A2	19940823	JP 1994-1244		19940111	
JP 2505978	B2	19960612				
			CH 1993-123	A	19930115	
FI 9400147	A	19940716	FI 1994-147		19940112	
			CH 1993-123	A	19930115	
BR 9400082	A	19940802	BR 1994-82		19940112	
			CH 1993-123	A	19930115	
CN 1097727	A	19950125	CN 1994-100624		19940113	
			CH 1993-123	A	19930115	
NO 9400143	A	19940718	NO 1994-143		19940114	
NO 180630	B	19970210				
NO 180630	C	19970521				
			CH 1993-123	A	19930115	
US 5385947	A	19950131	US 1994-252131		19940531	
			CH 1993-123	A	19930115	
			US 1994-179215	B1	19940110	

OS MARPAT 122:239346

AB Title compds. [I; R1,R2 = H, (cycloalkyl)alkyl, aralkyl; R3 = H, alkanoyl; R4 = R5 = H or halo; 1 of R4,R5 = H and the other = halo, OH, alkoxy, aryloxy, NH2] were prepared Thus, 7-benzyloxy-1,2,3,4-tetrahydronaphthalen-1-one was α-gem-dialkylated with Br(CH2)4Br and the methylenated product cyclocondensed with ClSO2NCO to give butanonaphthofuranylidenesulfamoyl chloride II which was treated with LAH and the deprotected product acidified to give racemic I.HCl (R1 = R2 = R5 = H, R4 = 3-OH). The latter had IC50 of 73.4nM against dizocilpine binding at rat cortex.

IT 162180-66-7P 162180-68-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and decomposition of, in preparation of NMDA antagonist)

RN 162180-66-7 CAPLUS

CN 8a(4bH)-Phenanthrenol, 4b-(2-aminoethyl)-5,6,7,8,9,10-hexahydro-3-(phenylmethoxy)-, cis-(+)-, compd. with (R)-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin 4-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 162180-65-6
CMF C23 H29 N O2

Rotation (+). Absolute stereochemistry unknown.



CM 2

CRN 39648-67-4
CMF C20 H13 O4 P



RN 162180-68-9 CAPLUS
CN 8a(4bH)-Phenanthrenol, 4b-(2-aminoethyl)-5,6,7,8,9,10-hexahydro-3-(phenylmethoxy)-, cis-(-)-, compd. with (S)-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin 4-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 162180-67-8
CMF C23 H29 N O2

Rotation (-). Absolute stereochemistry unknown.



CM 2

CRN 35193-64-7
CMF C20 H13 O4 P



IT 162180-13-4P 162180-14-5P 162180-15-6P
162180-21-4P 162180-25-8P 162180-29-2P
162180-48-5P 162180-49-6P 162180-51-0P
162180-52-1P 162180-53-2P 162180-54-3P
162180-55-4P 162180-56-5P 162180-57-6P
162180-58-7P 162180-59-8P 162180-63-4P
162180-64-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of NMDA antagonist)
RN 162180-13-4 CAPLUS
CN 8a(4bH)-Phenanthrenol, 4b-(2-aminoethyl)-5,6,7,8,9,10-hexahydro-3-(phenylmethoxy)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-14-5 CAPLUS
CN Formamide, N-[2-[1,3,4,9,10,10a-hexahydro-10a-hydroxy-6-(phenylmethoxy)-4a(2H)-phenanthrenyl]ethyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-15-6 CAPLUS
CN 8a(4bH)-Phenanthrenol, 5,6,7,8,9,10-hexahydro-4b-[2-(methylamino)ethyl]-3-(phenylmethoxy)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-21-4 CAPLUS
CN 8a(4bH)-Phenanthrenol, 4b-(2-aminoethyl)-5,6,7,8,9,10-hexahydro-1-(phenylmethoxy)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-25-8 CAPLUS
CN 8a(4bH)-Phenanthrenol, 4b-(2-aminoethyl)-5,6,7,8,9,10-hexahydro-2-(phenylmethoxy)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-29-2 CAPLUS
CN 8a(4bH)-Phenanthrenol, 4b-(2-aminoethyl)-5,6,7,8,9,10-hexahydro-4-(phenylmethoxy)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-48-5 CAPLUS
CN Acetamide, N-[2-[1,3,4,9,10,10a-hexahydro-10a-hydroxy-6-(phenylmethoxy)-4a(2H)-phenanthrenyl]ethyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-49-6 CAPLUS
CN 8a(4bH)-Phenanthrenol, 4b-[2-(ethylamino)ethyl]-5,6,7,8,9,10-hexahydro-3-(phenylmethoxy)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-51-0 CAPLUS
CN 8a(4bH)-Phenanthrenol, 4b-[2-(diethylamino)ethyl]-5,6,7,8,9,10-hexahydro-3-(phenylmethoxy)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-52-1 CAPLUS
CN Propanamide, N-[2-[1,3,4,9,10,10a-hexahydro-10a-hydroxy-6-(phenylmethoxy)-4a(2H)-phenanthrenyl]ethyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-53-2 CAPLUS
CN 8a(4bH)-Phenanthrenol, 5,6,7,8,9,10-hexahydro-3-(phenylmethoxy)-4b-[2-(propylamino)ethyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-54-3 CAPLUS
CN Cyclopropanecarboxamide, N-[2-[1,3,4,9,10,10a-hexahydro-10a-hydroxy-6-(phenylmethoxy)-4a(2H)-phenanthrenyl]ethyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-55-4 CAPLUS
CN 8a(4bH)-Phenanthrenol, 4b-[2-[(cyclopropylmethyl)amino]ethyl]-5,6,7,8,9,10-hexahydro-3-(phenylmethoxy)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-56-5 CAPLUS
CN Cyclobutanecarboxamide, N-[2-[1,3,4,9,10,10a-hexahydro-10a-hydroxy-6-

(phenylmethoxy)-4a(2H)-phenanthrenyl]ethyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-57-6 CAPLUS
CN 8a(4bH)-Phenanthrenol, 4b-[2-[(cyclobutylmethyl)amino]ethyl]-5,6,7,8,9,10-hexahydro-3-(phenylmethoxy)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-58-7 CAPLUS
CN Benzeneacetamide, N-[2-[1,3,4,9,10,10a-hexahydro-10a-hydroxy-6-(phenylmethoxy)-4a(2H)-phenanthrenyl]ethyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-59-8 CAPLUS

CN 8a(4bH)-Phenanthrenol, 5,6,7,8,9,10-hexahydro-4b-[2-[(2-phenylethyl)amino]ethyl]-3-(phenylmethoxy)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-63-4 CAPLUS
CN 8a(4bH)-Phenanthrenol, 4b-[2-(dimethylamino)ethyl]-5,6,7,8,9,10-hexahydro-3-(phenylmethoxy)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 162180-64-5 CAPLUS
CN 8a(4bH)-Phenanthrenol, 4b-[2-(dimethylamino)ethyl]-5,6,7,8,9,10-hexahydro-3-(phenylmethoxy)-, acetate (ester), cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:37641 CAPLUS
DN 122:56495
TI Synthetic Receptor for Internal Residues of a Peptide Chain. Highly Selective Binding of (L)X-(L)Pro-(L)X Tripeptides
AU Borchardt, Allen; Still, W. Clark
CS Department of Chemistry, Columbia University New York, New York, NY, 10027, USA
SO Journal of the American Chemical Society (1994), 116(16), 7467-8
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA English
OS CASREACT 122:56495
AB New C3-sym., synthetic receptors I and II for peptides is described. Binding studies on solid supports and in solution show not only that I exhibits high selectivity for binding tripeptides containing an internal L-proline (>99% de for L-Pro vs. D-Pro), but also binds L-Pro more tightly than cyclic analogs which are both smaller and larger than Pro itself. Furthermore, I stereoselectively binds substrates having l-amino acids adjacent to l-Pro (90-99% de for L-Ala) and with binding consts. (Ka = 2.5 + 105 for iPrCO-L-Ala-L-Pro-L-Ala) that are among the largest reported for binding a neutral guest by a synthetic host. These binding properties are very different from a previously described C3-sym. receptor having benzenes in place of the naphthalenes of I and that bound terminal peptide residues instead of the internal residues bound by I.
IT 159948-01-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and macrocyclization of)
RN 159948-01-3 CAPLUS
CN 2-Naphthalenecarboxylic acid, 7-[[[2-amino-1-oxo-3-[4-(2-propenyloxy)phenyl]propyl]amino]methyl]-4-[[3,5-bis(bromomethyl)phenyl]methoxy]-, pentafluorophenyl ester, (S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 159948-00-2
CMF C39 H31 Br2 F5 N2 O5

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

CM 2

CRN 76-05-1
CMF C2 H F3 O2



L4 ANSWER 18 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:106569 CAPLUS
DN 120:106569
TI Preparation of polycyclic arylmethylaminoalkanols as neoplasm inhibitors
IN Bair, Kenneth W.

PA Burroughs Wellcome Co., USA
SO U.S., 12 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5241107	A	19930831	US 1985-798125	19851114
			GB 1984-28931 A	19841115

OS MARPAT 120:106569
AB ArCH2R1 [Ar = (substituted) fused tetracarbocyclic or pentacarbocyclic aromatic ring system which is planar or nearly so; R1 = NR5CR6R7(CH2)mCR8R9OH, Q1; R5 = H; R6, R7 = H, (hydroxy)alkyl; R8, R9 = H, alkyl; R10 = H, Me, CH2OH; R11-R13 = H, Me; R14 = H, Me, OH, CH2OH; ring A in Q1 is a 5-6 membered carbocycle] and ether derivs. thereof, were prepared Thus, 1-[2-(methoxy)ethoxy]anthracene-1-carboxaldehyde (preparation from 1-chloroanthraquinone given) was refluxed with 2-amino-2-methyl-1,3-propanediol and 4-MeC6H4SO3H with azeotropic removal of H2O; the mixture was cooled, diluted with EtOH, and treated with NaBH4 to give 2-[[[4-[2-(methoxy)ethoxy]-1-anthracenyl]methyl]amino]-2-methyl-1,3-propanediol, isolated as the hydrochloride. Title compds. at 45-260 mg/kg i.p. in mice injected with P388 leukemia gave T/C values of 121-285%. Generic drug formulations are given.
IT 152644-17-2P 152644-18-3P 152644-19-4P
152644-20-7P 152644-21-8P 152644-22-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as neoplasm inhibitor)
RN 152644-17-2 CAPLUS
CN 1,3-Propanediol, 2-methyl-2-[[[9-(phenylmethoxy)-1-pyrenyl]methyl]amino]-, methanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 152644-16-1
CMF C28 H27 N O3



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 152644-18-3 CAPLUS
CN Ethanesulfonic acid, compd. with 2-methyl-2-[[[9-(phenylmethoxy)-1-pyrenyl]methyl]amino]-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152644-16-1
CMF C28 H27 N O3



CM 2

CRN 594-45-6
CMF C2 H6 O3 S



RN 152644-19-4 CAPLUS
CN Propanoic acid, 2-hydroxy-, compd. with 2-methyl-2-[[[9-(phenylmethoxy)-1-pyrenyl]methyl]amino]-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152644-16-1
CMF C28 H27 N O3



CM 2

CRN 50-21-5
CMF C3 H6 O3



RN 152644-20-7 CAPLUS
CN 1,3-Propanediol, 2-methyl-2-[[[9-(phenylmethoxy)-1-pyrenyl]methyl]amino]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 152644-16-1
CMF C28 H27 N O3



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 152644-21-8 CAPLUS
CN Ethanesulfonic acid, 2-hydroxy-, compd. with 2-methyl-2-[[[9-(phenylmethoxy)-1-pyrenyl]methyl]amino]-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152644-16-1
CMF C28 H27 N O3



CM 2

CRN 107-36-8
CMF C2 H6 O4 S



RN 152644-22-9 CAPLUS
CN 1,3-Propanediol, 2-methyl-2-[[[9-(phenylmethoxy)-1-pyrenyl]methyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 19 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:106566 CAPLUS
DN 120:106566
TI Preparation of naphthylalkylamines as melatonin antagonists
IN Yous, Said; Lesieur, Daniel; Depreux, Patrick; Guardiola-Lemaitre, Beatrice; Adam, Gerard; Renard, Pierre; Caignard, Daniel Henri
PA ADIR et Co., Fr.
SO Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 562956	A1	19930929	EP 1993-400757	19930324
	EP 562956	B1	19950927		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				FR 1992-3700 A	19920327
	FR 2689124	A1	19931001	FR 1992-3700	19920327

US 5420158	A	19950530	US 1993-35936		19930323
			FR 1992-3700	A	19920327
AT 128458	E	19951015	AT 1993-400757		19930324
			FR 1992-3700	A	19920327
ES 2081187	T3	19960216	ES 1993-400757		19930324
			FR 1992-3700	A	19920327
CA 2092794	AA	19930928	CA 1993-2092794		19930326
CA 2092794	C	19990323			
			FR 1992-3700	A	19920327
AU 9335445	A1	19930930	AU 1993-35445		19930326
AU 657400	B2	19950309			
			FR 1992-3700	A	19920327
ZA 9302168	A	19931108	ZA 1993-2168		19930326
			FR 1992-3700	A	19920327
JP 06049011	A2	19940222	JP 1993-105844		19930326
JP 07049404	B4	19950531			
			FR 1992-3700	A	19920327
US 5616614	A	19970401	US 1995-377812		19950125
			FR 1992-3700	A	19920327
			US 1993-35936	A3	19930323

OS MARPAT 120:106566

AB Title compds. [I; R = H, OR4; R1 = H, CO2R5; R2 = H, (substituted) alkyl; R3 = CO(CH2)nR6, C(:X)NH(CH2)mR7; R4 = H, (cyclo)alkyl, (di)phenyl(alkyl), etc.; R5 = H, alkyl; R6 = H, (cyclo)alkyl, alkenyl, heterocyclyl, etc.; R7 = (cyclo)alkyl, Ph, etc.; X = O, S; m, n = 0-3] were prepared Thus, cyclobutanecarbonyl chloride was amidated by 2-(1-naphthyl)ethylamine to give title compound II, which gave significant (sic) antagonism of melatonin-induced pigment aggregation in amphibian dermal melanophores at 10-7 M in vitro.

IT 152302-41-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as melatonin antagonist)

RN 152302-41-5 CAPLUS

CN Cyclopropanecarboxamide, N-[2-[7-(phenylmethoxy)-1-naphthalenyl]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1992:645710 CAPLUS

DN 117:245710

TI Novel naphthalenic ligands for the melatonin receptor

AU Adam, G.; Guardiola-Lemaitre, B.; Yous, S.; Lesieur, D.; Morgan, P.; Howell, H. E.; Andrieux, J.; Caignard, D. H.; Pfeiffer, B.; Renard, P.

CS IRIS-Servier, Courbevoie, F-92415, Fr.
SO Journal de Pharmacie de Belgique (1992), 47(4), 374-80
CODEN: JPBEAJ; ISSN: 0047-2166
DT Journal
LA French
AB Twenty-three naphthalenic stereoisomers of melatonin, of the type I which vary mainly in acylamino substituents of the side chain and the alkoxy group on position 7 of the naphthalene, were prepared and examined for affinity at the melatonin receptor in pars tuberalis of sheep. The biol. activities of the melatonin analogs were discussed in relation to their mol. structures. Results also provide information on the mode of interaction at the melatonin binding site.
IT 144489-23-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and melatonin receptor affinity of)
RN 144489-23-6 CAPLUS
CN Acetamide, N-[2-[7-(phenylmethoxy)-1-naphthalenyl]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:158021 CAPLUS
DN 112:158021
TI Preparation of quinone imine ketals via intramolecular condensation of amino-substituted quinone monoketals. Anodic oxidation chemistry of trifluoroacetamide derivatives of 1,4-dimethoxybenzenes and 4-methoxyphenols
AU Swenton, John S.; Shih, Chuan; Chen, Chung Pin; Chou, Chun Tzer
CS Dep. Chem., Ohio State Univ., Columbus, OH, 43210, USA
SO Journal of Organic Chemistry (1990), 55(7), 2019-26
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English
OS CASREACT 112:158021
AB Two routes have been developed to the previously unknown quinone ketal moiety. One involves a sequence of anodic oxidation of the N-trifluoroacetamide of a 2-(2,5-dimethoxyphenyl)ethylamine (I; n = 1, R = OMe, Br) or 3-(2,5-dimethoxyphenyl)propylamine (I; n = 2) to form the resp. quinone bisketal followed by basic hydrolysis of the trifluoroacetamide linkage, acidic hydrolysis of the quinone bisketal to a quinone monoketal and intramol. condensation to form the quinone imine ketal II (R1 = R2 = H). This method requires the bromo or methoxy substituent to direct the regiochem. of the quinone bisketal hydrolysis. The second method involves similar chemical except that the anodic oxidation of 4-methoxyphenol III (n = 1, 2; R1 = R2 = H; R1 = H, Me, R1 = OH) directly affords the quinone monoketal. Hydrolysis of the trifluoroacetamide followed by an intramol. condensation reaction affords the quinone imine ketal II. Selected aspects of the chemical of these compds. have been studied. Especially interesting is the reaction of quinone imine ketal III (n = 1, R1 = Me, R2 = OH) with MeLi, PhLi, BuLi, Me3Li, EtCHMeLi. Either 1- or 2-substituted-5-methoxyindole is produced, depending upon the

organolithium compound
IT 125438-59-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and debenzylation of)
RN 125438-59-7 CAPLUS
CN Acetamide, 2,2,2-trifluoro-N-[[1,2,3,4-tetrahydro-1-hydroxy-5-methoxy-8-(phenylmethoxy)-1-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



IT 125438-58-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and trifluoroacetylation of)
RN 125438-58-6 CAPLUS
CN 1-Naphthalenol, 1-(aminomethyl)-1,2,3,4-tetrahydro-5-methoxy-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1984:51453 CAPLUS
DN 100:51453
TI Bicyclic benzo-fused compounds
IN Eggler, James Frederick; Johnson, Michael Ross; Melvin, Lawrence Sherman
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 121 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 89781	A2	19830928	EP 1983-301289	19830309
	EP 89781	A3	19850814		

	EP 89781	B1	19900808			
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
				US 1982-358751	A	19820316
				US 1983-457171	A	19830113
	US 4486428	A	19841204	US 1983-457171		19830113
				US 1982-358751	A2	19820316
	AT 55381	E	19900815	AT 1983-301289		19830309
				US 1982-358751	A	19820316
				US 1983-457171	A	19830113
				EP 1983-301289	A	19830309
	CS 249135	B2	19870312	CS 1984-3305		19840504
				US 1982-358751	A	19820316
				CS 1983-1823	A3	19830316

PATENT FAMILY INFORMATION:

FAN 1985:578170

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 4486428	A	19841204	US 1983-457171		19830113
				US 1982-358751	A2	19820316
	DK 8300856	A	19831005	DK 1983-856		19830224
				US 1982-358751	A	19820316
				US 1983-457171	A	19830113
	EP 89781	A2	19830928	EP 1983-301289		19830309
	EP 89781	A3	19850814			
	EP 89781	B1	19900808			
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
				US 1982-358751	A	19820316
				US 1983-457171	A	19830113
	AT 55381	E	19900815	AT 1983-301289		19830309
				US 1982-358751	A	19820316
				US 1983-457171	A	19830113
				EP 1983-301289	A	19830309
	IL 68117	A1	19860331	IL 1983-68117		19830314
				US 1982-358751	A	19820316
				US 1983-457171	A	19830113
	CA 1215984	A1	19861230	CA 1983-423540		19830314
				US 1982-358751	A	19820316
				US 1983-457171	A	19830113
	FI 8300858	A	19830917	FI 1983-858		19830315
	FI 80026	B	19891229			
	FI 80026	C	19900410			
				US 1982-358751	A	19820316
				US 1983-457171	A	19830113
	NO 8300901	A	19830919	NO 1983-901		19830315
	NO 167388	B	19910722			
	NO 167388	C	19911030			
				US 1982-358751	A	19820316
				US 1983-457171	A	19830113
	AU 8312447	A1	19831006	AU 1983-12447		19830315
	AU 540001	B2	19841025			
				US 1982-358751	A	19820316
				US 1983-457171	A	19830113
	ZA 8301783	A	19831130	ZA 1983-1783		19830315
				US 1982-358751	A	19820316
	ES 520631	A1	19840416	ES 1983-520631		19830315
				US 1982-358751	A	19820316
				US 1983-457171	A	19830113
	DD 211559	A5	19840718	DD 1983-248823		19830315
				US 1982-358751	A	19820316
				US 1983-457171	A	19830113
	HU 33135	0	19841029	HU 1983-877		19830315

HU 196983	B	19890228			
			US 1982-358751	A	19820316
			US 1983-457171	A	19830113
DD 219764	A5	19850313	DD 1983-265393		19830315
			US 1982-358751	A	19820316
			US 1983-457171	A	19830113
RO 87060	B3	19850831	RO 1983-110333		19830315
			US 1983-457171	A	19830113
PL 140273	B1	19870430	PL 1983-241025		19830315
			US 1983-457171	A	19830113
PL 140284	B1	19870430	PL 1983-249965		19830315
			US 1982-358751	A	19820316
SU 1316563	A3	19870607	SU 1983-3568915		19830315
			US 1982-358751	A	19820316
			US 1983-457171	A	19830113
RO 91185	B3	19870630	RO 1983-118149		19830315
			US 1982-358751		19820316
HU 194853	B	19880328	HU 1986-2058		19830315
			US 1982-358751	A	19820316
JP 58180456	A2	19831021	JP 1983-42539		19830316
JP 02042832	B4	19900926			
			US 1982-358751	A	19820316
			US 1983-457171	A	19830113
CS 249127	B2	19870312	CS 1983-1823		19830316
			US 1983-457171	A	19830113
ES 527119	A1	19850501	ES 1983-527119		19831108
			US 1982-358751	A	19820316
			US 1983-457171	A	19830113
CS 249135	B2	19870312	CS 1984-3305		19840504
			US 1982-358751	A	19820316
			CS 1983-1823	A3	19830316
US 4680404	A	19870714	US 1984-639151		19840809
			US 1982-358751	A2	19820316
			US 1983-457171	A3	19830113
US 4841078	A	19890620	US 1984-639038		19840809
			US 1982-358751	A2	19820316
			US 1983-457171	A3	19830113
AU 557746	B2	19870108	AU 1984-32061		19840817
AU 8432061	A1	19850110			
			US 1982-358751		19820316
FI 8504329	A	19851104	FI 1985-4329		19851104
FI 88158	B	19921231			
FI 88158	C	19930413			
			US 1982-358751	A	19820316
			US 1983-457171	A	19830113
			FI 1983-858	A	19830315
US 4863934	A	19890905	US 1988-278634		19881201
			US 1982-358751	A2	19820316
			US 1983-457171	A3	19830113
			US 1984-639038	A3	19840809
US 4870084	A	19890926	US 1988-278635		19881201
			US 1982-358751	A2	19820316
			US 1983-457171	A3	19830113
			US 1984-639038	A3	19840809

OS MARPAT 100:51453

AB About 100 pharmacol. active (no data) title compds. I [R = H, Me, Et; R1 = H, alkyl, aralkyl; R2 = H, substituted alkyl; R3 = H, substituted alkyl, substituted acyl, 5-tetrazolyl, cyano; R4 = H, OH; R3R4 = heterocyclic; R5 = H, CH2Ph, Bz, (un)substituted alkanoyl; R3R5 = (un)substituted CH2CH2O, CH2CO2; R6 = (un)substituted alkylene, alkyl; X = O, CH2, (un)substituted NH] were prepared Thus 1,3-(HO)2C6H3CMe2(CH2)5Me-5 was treated with

Me2C:CHCO2H to give benzopyranone II (R7 = H) which was treated with PhCH2Br to give II (R7 = CH2Ph). The last was lithiated and treated with EtOAc to give benzopyran III (R7 = CH2Ph, R8 = OH, R9 = Et), which underwent hydrogenolysis in MeOH to give III (R7 = R8 = H, R9 = Me).

IT 88464-86-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and debenzylation of)

RN 88464-86-2 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[[1,2,3,4-tetrahydro-3,3-dimethyl-6-(1-methyl-4-phenylbutoxy)-8-(phenylmethoxy)-1-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



IT 88464-94-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and trifluoroacetylation of)

RN 88464-94-2 CAPLUS

CN 1-Naphthalenemethanamine, 1,2,3,4-tetrahydro-3,3-dimethyl-6-(1-methyl-4-phenylbutoxy)-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1983:594583 CAPLUS

DN 99:194583

TI Attempts to develop novel dopamine agonists: 1-aminomethyl-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene and 1-aminomethyl-5,6-dihydroxy-2,3-dihydroindene

AU Nichols, David E.; Jadhav, Kiran P.; Buzdor, Roy A.

CS Sch. Pharm. Pharm. Sci., Purdue Univ., West Lafayette, IN, 47907, USA

SO Acta Pharmaceutica Suecica (1983), (Suppl. 2, Dopamine Recept. Agonists 2), 65-74
CODEN: APSXAS; ISSN: 0001-6675

DT Journal

LA English

AB Tetralone and indanone I (RR1 = O, R2 = H, R3 = Me; n = 0, 1) were treated with Me3SiCN to give I (R = OSiMe3, R1 = CN) which were reduced and dehydrated to give I (R = CH2NH2, R1R2 = bond). The latter was

hydrogenated to give I (R = CH2NH2, R1 = R2 = H, R3 = Me; II). Demethylation of of II (n = 0) gave I (R = CH2NH2, R1 = R2 = H, R3 = H, III). II (n = 1) was protected to give I (R = CH2NHCHO, R1 = R2 = H, R3 = Me), which was treated with BBr3 and realkylated to form I (R = CH2NHCHO, R1 = R2 = H, R3 = CH2Ph). Hydrolysis and hydrogenolysis of the latter gave I (R = CH2NH2.HBr; R1 = R2 = H; R3 = H; IV). III and IV were inactive as dopamine agonists in the canine renal blood flow assay at ≤3000 nmol intraarterially.

IT 87731-11-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and debenzylation of)

RN 87731-11-1 CAPLUS

CN 1-Naphthalenemethanamine, 1,2,3,4-tetrahydro-6,7-bis(phenylmethoxy)- (9CI) (CA INDEX NAME)



IT 87731-10-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 87731-10-0 CAPLUS

CN Formamide, N-[[1,2,3,4-tetrahydro-6,7-bis(phenylmethoxy)-1-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1979:55153 CAPLUS

DN 90:55153

TI 6-Aminoalkyl catechol estrogens: models of steroidal biogenic amines

AU Takadate, Akira; Fishman, Jack

CS Rockefeller Univ., New York, NY, USA

SO Journal of Organic Chemistry (1979), 44(1), 67-71
CODEN: JOCEAH; ISSN: 0022-3263

DT Journal

LA English

AB Treating 2,3-dibenzyloxy-17β-acetoxyestra-1,3,5(10)-trien-6-one (I) with Me3SiCN gave only the 6β-cyano-6α-(trimethylsilyloxy) derivative (II). Subsequent reductive elaboration of II gave 6β-(aminoethyl)estra-1,3,5(10)-triene-2,3,6α,17β-tetrol, which combines the structural features of the centrally active catechol estrogens and the biogenic catecholamines. 6α- And 6β-(2-acetaminoethyl)estra-1,3,5(10)-triene-2,3,17β-triol triacetates were prepared via Wittig reaction of I with (EtO2)P(O)CH2CN and

subsequent reduction
IT 68129-08-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)
RN 68129-08-8 CAPLUS
CN Estra-1,3,5(10)-triene-6,17-diol, 6-(aminomethyl)-2,3-bis(phenylmethoxy)-, (6α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 25 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1970:466342 CAPLUS
DN 73:66342
TI Sedative and tranquilizing 2-hydroxy-9,10-dihydro-9,10-ethanoanthracenes
IN Wilhelm, Max
PA CIBA Ltd.
SO Ger. Offen., 33 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	DE 1964797	A	19700716	DE 1969-1964797		19691224
				CH 1969-13	A	19690103
				CH 1969-17952	A	19691202
	CH 513108	A	19710930	CH 1969-513108		19690103
				CH 1969-13	A	19690103
	CH 548977	A	19740515	CH 1969-17952	A	19691202
	US 3706765	A	19721219	US 1969-885646		19691216
				CH 1969-1369	A	19690103
				CH 1969-17952	A	19691202
	GB 1290696	A	19720927	GB 1969-1290696		19691218
				CH 1969-13	A	19690103
				CH 1969-17952	A	19691202
	FR 2027709	A5	19701002	FR 1969-44781		19691224
				CH 1969-13	A	19690103
	SU 416941	D	19740225	SU 1969-1603689		19691230
				CH 1969-13	A	19690103
	SU 433671	D	19740625	SU 1969-1603690		19691230
				CH 1969-13	A	19690103
				CH 1969-17952	A	19691212

HU 163391	P	19730828	HU 1969-CI949		19691231
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
BE 743993	A	19700702	BE 1970-743993		19700102
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
NL 7000017	A	19700707	NL 1970-17		19700102
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
ES 375129	A1	19720316	ES 1970-375129		19700102
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
AT 299173	B	19720612	AT 1970-24		19700102
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
AT 304495	B	19730110	AT 1970-9112		19700102
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
AT 304496	B	19730110	AT 1970-9113		19700102
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
AT 304497	B	19730110	AT 1970-9115		19700102
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
AT 304498	B	19730110	AT 1970-9116		19700102
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
AT 304508	B	19730110	AT 1971-6489		19700102
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
AT 304509	B	19730110	AT 1971-6492		19700102
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
SE 366024	B	19740408	SE 1970-2		19700102
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
DK 129699	B	19741111	DK 1970-6		19700102
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
PL 80814	P	19750830	PL 1970-137934		19700102
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
CS 164839	P	19751128	CS 1970-19		19700103
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
CS 164840	P	19751128	CS 1970-8017		19700103
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
CS 164841	P	19751128	CS 1970-8018		19700103
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
CS 164843	P	19751128	CS 1970-8020		19700103
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
CS 164844	P	19751128	CS 1970-8021		19700103
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
CS 164845	P	19751128	CS 1970-8022		19700103
			CH 1969-13	A	19690103
			CH 1969-17952	A	19691202
CS 164842	P	19751128	CS 1972-8019		19700103

CH 1969-13 A 19690103
CH 1969-17952 A 19691202

AB The title compds. (I) (R2 = OH, R = R1 = Me; or R = H, R1 = Me) and I (R2 = MeO, R = R1 = Me) useful as sedatives, tranquilizers, and additives for animal foods, were prepared Thus, diazotation of I (R = R1 = Me, R2 = NH2) (Ia) and treatment with concentrated H2SO4 at 80° gave I (R = R1 = Me, R2 = Oh), which was alkylated with CH2N2 to give I (R = R1 = Me, R2 = MeO). Treatment of II (R2 = H, R3 = CHO) with concentrated HNO3 gave II (R2 = NO2, R3 = CHO), which was treated with H2NMe to give II (R2 = NO2, R3 = CH:NMe) (IIa). On reduction with NaBH4, IIa gave I (R = H, R1 = Me, R2 = NO2), which was treated with HCHO and HCO2H to give I (R = R1 = Me, R2 = NO2), which was hydrogenated over Raney Ni to give Ia.

IT 29747-43-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 29747-43-1 CAPLUS

CN 9,10-Ethanoanthracene-9(10H)-methylamine, 2-(benzyloxy)-N-methyl-, hydrochloride (8CI) (CA INDEX NAME)



● HCl

=>